» Articles » PMID: 38565930

An Observational Study to Identify Causative Factors for Not Using Hydroxychloroquine in Systemic Lupus Erythematosus

Overview
Journal Sci Rep
Specialty Science
Date 2024 Apr 2
PMID 38565930
Authors
Affiliations
Soon will be listed here.
Abstract

Hydroxychloroquine (HCQ) use is indicated for patients with systemic lupus erythematosus (SLE). Nevertheless, reports discussing the reasons for not prescribing HCQ are limited. We identified the factors that interfere with HCQ use in patients with SLE. This observational, single-center study included data from 265 patients with SLE in 2019. The patients were categorized into groups with and without a history of HCQ use. Between these groups, clinical characteristics were compared using univariate analysis and logistic regression models. Among the 265 patients, 133 (50.2%) had a history of HCQ use. Univariate analysis identified older age; longer disease duration; lower prednisolone dose, clinical SLE disease activity index 2000, and estimated glomerular filtration rate; higher C3 level; and lower anti-double-stranded DNA antibody concentration as HCQ non-use-related variables. Logistic regression models identified a positive association between HCQ non-use and longer disease duration (odds ratio [OR] 1.08), prednisolone dose ≤ 7.5 mg/day (OR 4.03), C3 level ≥ 73 mg/dL (OR 2.15), and attending physician having graduated > 10 years prior (OR 3.19). In conclusion, a longer disease duration, lower prednisolone dose, higher C3 level, and longer time since attending physicians' graduation correlated with HCQ non-use. Physicians and patients should be educated to facilitate HCQ use despite these factors.

References
1.
Saito M, Yajima N, Yanai R, Tsubokura Y, Ichinose K, Yoshimi R . Prevalence and treatment conditions for hypertension and dyslipidaemia complicated with systemic lupus erythematosus: A multi-centre cross-sectional study. Lupus. 2021; 30(7):1146-1153. DOI: 10.1177/09612033211006790. View

2.
Uribe A, Vila L, McGwin Jr G, Sanchez M, Reveille J, Alarcon G . The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004; 31(10):1934-40. View

3.
Harrold L, Patel P, Griffith J, Litman H, Feng H, Schlacher C . Assessing disease severity in bio-naïve patients with RA on treatment with csDMARDs: insights from the Corrona Registry. Clin Rheumatol. 2019; 39(2):391-400. DOI: 10.1007/s10067-019-04727-7. View

4.
Ho A, Magder L, Barr S, Petri M . Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 2001; 44(10):2342-9. DOI: 10.1002/1529-0131(200110)44:10<2342::aid-art397>3.0.co;2-8. View

5.
Giannakou I, Chatzidionysiou K, Magder L, Gyori N, van Vollenhoven R, Petri M . Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. Lupus Sci Med. 2018; 5(1):e000287. PMC: 6257375. DOI: 10.1136/lupus-2018-000287. View